http://rdf.ncbi.nlm.nih.gov/pubchem/reference/12429020

Outgoing Links

Predicate Object
contentType Clinical Trial|Journal Article|Multicenter Study
endingPage 244
issn 0277-3732
issueIdentifier 3
pageRange 239-244
publicationName American Journal of Clinical Oncology
startingPage 239
bibliographicCitation Di Leo A, Bajetta E, Buzzoni R, Bochicchio AM, Nolè F, Biganzoli L, D'Aprile M, Veltri E, Comella G, Aitini E. Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer. A study by the Italian Trials in Medical Oncology Group. Am J Clin Oncol. 1995 Jun;18(3):239–44. doi: 10.1097/00000421-199506000-00011. PMID: 7538260.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5b5837115a6f7fc24b57425583abdf85
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_773a16a1258f329ed7e601f2e1c3e9a0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6ec603348a897e6eecbb5bc175c5b57e
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_41f70291bae0ae26784eb38bf69a6da8
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b677e6be56bbd1e98d93b571e6ffd93f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_61a9a4e75d783a24eec2a7a79def861b
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f472fb11ce62c436eae00249e2c5b9b4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-9436-2384
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-7989-8658
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_0d9ae2ce543827cf66c90a453664b7e6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_60c2c909baf1f80bf05d10f119463d03
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5ef0d6f0b36e3e444762e6b004168b67
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_3c560cda08a25987f35fbfd320429746
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_7f07099ebdd558a60580db69d09e0d74
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8dea0d200ee5c8db1dacb9fdea9ea816
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_6d6394bdd354b3eb8342c3507584d8f7
date 199506
identifier https://pubmed.ncbi.nlm.nih.gov/7538260
https://doi.org/10.1097/00000421-199506000-00011
isPartOf https://portal.issn.org/resource/ISSN/0277-3732
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/413
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer. A study by the Italian Trials in Medical Oncology Group
discusses http://id.nlm.nih.gov/mesh/M0026185
http://id.nlm.nih.gov/mesh/M0023488
hasPrimarySubjectTerm http://id.nlm.nih.gov/mesh/D017258Q000627
http://id.nlm.nih.gov/mesh/D001859Q000556
http://id.nlm.nih.gov/mesh/D001859Q000188
http://id.nlm.nih.gov/mesh/D010166
http://id.nlm.nih.gov/mesh/D009376Q000188
http://id.nlm.nih.gov/mesh/D015251Q000627
http://id.nlm.nih.gov/mesh/D011471Q000188
hasSubjectTerm http://id.nlm.nih.gov/mesh/D015251Q000008
http://id.nlm.nih.gov/mesh/D000368
http://id.nlm.nih.gov/mesh/D001859Q000503
http://id.nlm.nih.gov/mesh/D008875
http://id.nlm.nih.gov/mesh/D004359
http://id.nlm.nih.gov/mesh/D010147
http://id.nlm.nih.gov/mesh/D004357
http://id.nlm.nih.gov/mesh/D015251Q000009
http://id.nlm.nih.gov/mesh/D010146Q000209
http://id.nlm.nih.gov/mesh/D010146Q000188
http://id.nlm.nih.gov/mesh/D000553
http://id.nlm.nih.gov/mesh/D006333Q000139
http://id.nlm.nih.gov/mesh/D016019
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D017258Q000009
http://id.nlm.nih.gov/mesh/D008297
http://id.nlm.nih.gov/mesh/D017258Q000008
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID64747
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10631
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8983
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID41867
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6279
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11499
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8756

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID53786776
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID53787927

Total number of triples: 69.